RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Nazarius Lamango to Adenocarcinoma

Back to Details
This is a "connection" page, showing publications Nazarius Lamango has written about Adenocarcinoma.
Nazarius Lamango
Connection Strength
0.186
Adenocarcinoma
  1. Gregory MD, Ofosu-Asante K, Lazarte JMS, Puente PE, Tawfeeq N, Belony N, Huang Y, Offringa IA, Lamango NS. Treatment of a mutant KRAS lung cancer cell line with polyisoprenylated cysteinyl amide inhibitors activates the MAPK pathway, inhibits cell migration and induces apoptosis. PLoS One. 2024; 19(10):e0312563.
    View in: PubMed
    Score: 0.186
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support